Company intelligence / Profile preview

Pharmapark

Moscow, Moscow region, Russiapharmapark.ru ↗

Ownership: Private
Employees: ~35
Development stage: Commercial

Overview

Pharmapark has successfully developed and commercialized several biosimilars approved in Russia/CIS markets. These include filgrastim for neutropenia, epoetin beta for anemia, and interferon alfa‑2b for hepatitis C. The company also participates in technology transfer/localization projects with international partners to bring additional monoclonal antibody therapies to market.

Therapeutic areas: GastroenterologyOncologyRheumatologyImmunologyHematologyNeurologyInfectious Diseases
Modalities: BiosimilarMonoclonal antibodyInterferonColony-stimulating factorRecombinant protein
Industry: Biotech

Partnerships

Center of Genetic Engineering and Biotechnology of CubaWalvax Biotechnology Co., Ltd.Prestige Biopharma (South Korea)Bio-Thera Solutions Ltd. (China)

Beyond the preview

Go deeper on Pharmapark.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmapark.

Explore the full profile